证券代码：688136 证券简称：科兴制药 公告编号：2025-070 科兴生物制药股份有限公司 2025 年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 08 月 29 日 （二） 股东会召开的地点：深圳市南山区高新中一道与科技中一路交汇处创益 科技大厦 B 栋 19 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 84 | | --- | --- | | 普通股股东人数 | 84 | | 2、出席会议的股东所持有的表决权数量 | 121,857,761 | | 普通股股东所持有表决权数量 | 121,857,761 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 61.5110 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 61.511 ...

北京市嘉源律师事务所 关于科兴生物制药股份有限公司 2025年第一次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 滤律师事务所 A YUAN LAW OFFICES 北京 BEI JING·上海 SHANGHAI·深圳 SHENZHEN·香港 HONG KONG·广州 GUANGZHOU·西安 XI'AN 致:科兴生物制药股份有限公司 北京市嘉源律师事务所 关于科兴生物制药股份有限公司 2025年第一次临时股东大会的 法律意见书 嘉源(2025)-04-615 北京市嘉源律师事务所(以下简称"本所")接受科兴生物制药股份有限公 司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称"《公 司法》")《上市公司股东会规则》(以下简称"《股东会规则》")等现行有 效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规")以及《科 兴生物制药股份有限公司章程》(以下简称"《公司章程》")的有关规定,指 派本所律师对公司2025年第一次临时股东大会(以下简称"本次股东大会")进 行见证,并依法出具本法律意见书。 为出具本法律意见书,本所指派律师现场见证了本 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-071 科兴生物制药股份有限公司 关于完成董事会换届选举及 聘任高级管理人员、证券事务代表、审计监察部负责人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）于2025年8月29日分别召 开职工代表大会、2025年第一次临时股东会，选举产生了公司第三届董事会，任 期自2025年第一次临时股东会审议通过之日起三年。 （二）董事长及董事会专门委员会委员选举情况 2025 年 8 月 29 日，公司召开第三届董事会第一次会议，全体董事一致同意 选举邓学勤先生为公司第三届董事会董事长，并选举产生了公司第三届董事会战 略委员会、审计委员会、提名委员会、薪酬与考核委员会委员，具体情况如下： | 专门委员会 | 委员 | | 召集人 | | --- | --- | --- | --- | | 战略委员会 HE | RUYI、方俊辉、赵彦轻、崔宁 | HE RUYI | | | 审计委员会 | 张汉斌、方俊辉、黄凯昆 | 张汉 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-069 科兴生物制药股份有限公司 关于选举第三届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）第二届董事会任期已届满， 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券交易所 科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号— —规范运作》等法律法规、规范性文件的规定，公司于 2025 年 8 月 29 日召开 2025 年第一次临时股东会，审议通过了《关于取消监事会、变更注册资本暨修 订 <公司章程>的议案》等议案。根据修订后的《科兴生物制药股份有限公司章 程》（下称《公司章程》）规定，公司第三届董事会将由 4 名非独立董事、3 名 独立董事和 1 名职工董事组成，其中 1 名职工董事由职工代表大会选举产生。 公司于 2025 年 8 月 29 日召开职工代表大会，审议通过了《关于选举公司第 三届董事会职工代表董事的议案》，同意选举黄凯昆先生（简历 ...

Group 1 - The company, Sinovac Biotech, is planning to issue overseas listed shares (H-shares) and list on the Hong Kong Stock Exchange to enhance its international business development and competitiveness [1] - The H-share listing requires approval from the company's board, shareholders, and various regulatory bodies, indicating uncertainty in the process [1] - The company aims to leverage international capital market resources to optimize its capital structure and diversify financing channels [1] Group 2 - Sinovac Biotech's major shareholder, Shenzhen Keyi Pharmaceutical Holdings, plans to transfer 6,037,717 shares, representing 3.00% of the total share capital, due to funding needs [2] - The transfer price is set at 36.70 yuan per share, totaling approximately 221.58 million yuan [2] - Following the transfer, the shareholding of Keyi Pharmaceutical and its associated parties will decrease from 63.89% to 60.38% [2] Group 3 - Keyi Pharmaceutical previously reduced its holdings by 5,989,200 shares, or 3.00% of the total share capital, between June 26 and July 9, 2025, with a total amount of approximately 220.99 million yuan [3] - Over the past two months, Sinovac Biotech has realized approximately 443 million yuan from these transactions [4] - The company was listed on the Shanghai Stock Exchange on December 14, 2020, raising a total of 1.11 billion yuan, with a net amount of 999.5 million yuan after expenses [4][5]

Group 1 - The weight loss drug concept stocks experienced a decline in the afternoon trading session on August 28, with Meinuohua hitting the daily limit down [1] - MediXy and Kangyuan Pharmaceutical both fell over 7%, indicating a significant drop in their stock prices [1] - Other companies such as Kexing Pharmaceutical and Haixiang Pharmaceutical also reported notable declines in their stock performance [1]

Group 1 - The "A+H" listing model is gaining momentum, with nearly 20 A-share companies announcing plans to list in Hong Kong since August, indicating a strategic move towards internationalization [1][2] - The new IPO regulations effective from August 4 have provided significant impetus for this trend, allowing for a more flexible allocation mechanism and reducing compliance costs for A-share companies [1][2] - Companies like Greeenme have explicitly stated that their goal for listing in Hong Kong is to enhance their global strategy and improve their international brand image and competitiveness [1][3] Group 2 - Enterprises with large asset scales, high capital expenditures, and mature international operations are becoming the main players in the "A+H" model, utilizing the Hong Kong market for financing to support cross-border mergers and overseas expansions [2] - The "A+H" model is reshaping the valuation system and liquidity structure of Chinese listed companies, with significant foreign capital inflows into Hong Kong stocks, surpassing last year's total by 90% as of mid-2025 [2] - The dual listing structure helps mitigate valuation risks associated with market volatility, as seen with companies like CATL, which attracted substantial international long-term capital post-listing [2][3] Group 3 - There is a noticeable shift in the types of companies pursuing "A+H" listings, with more emerging sectors like renewable materials and biomedicine entering the fray, reflecting a deeper integration of China's tech industry with international capital markets [3] - The continued support from policies and the optimization of related systems are expected to propel the "A+H" model into a new phase of high-quality development, with more competitive Chinese companies likely to pursue this path for global capital and strategic positioning [3] - The maturation of the "A+H" model is a natural outcome of the ongoing deepening of China's capital market openness and a strategic choice for companies to enhance their international competitiveness [3]

Core Insights - The Chinese biopharmaceutical industry is experiencing a surge in performance, with 69.23% of 39 innovative drug companies reporting positive net profit growth in their semi-annual reports [1] - Six companies reported over 100% year-on-year growth in net profit, indicating strong development momentum in the sector [1] Company Performance - **Kexing Pharmaceutical** achieved the highest net profit growth at 576.45%, totaling 0.80 billion yuan, focusing on antiviral, oncology, and immunology treatments [1] - **Sanno Bio** reported a 308.29% increase in net profit, reaching 0.89 billion yuan, driven by significant growth in raw material drug sales [2][3] - **Jinkai Biotechnology** saw a 123.61% increase in net profit, providing custom development services for small molecule drugs [3] - **Wuxi AppTec** and **Hengrui Medicine** also ranked among the top three companies by revenue, with 207.99 billion yuan and 157.61 billion yuan respectively [4] Industry Trends - The industry is transitioning from an "investment phase" to a "harvest phase," indicating a recovery in profitability and a moderate expansion stage [4] - Recent policy measures from the National Healthcare Security Administration aim to support high-quality development in innovative drug research and market application [4] - Analysts predict that the innovative drug sector will continue to thrive, driven by efficiency and cost advantages in drug development [5]

Group 1 - Since August, nearly 20 A-share companies have announced plans to list in Hong Kong, with notable firms like Luxshare Precision and Victory Technology submitting H-share applications [1][5] - The primary motivations for these companies to pursue Hong Kong listings include expanding international strategies, optimizing overseas business layouts, enhancing brand recognition, and improving overseas financing capabilities [1][5] Group 2 - The recent A-share companies planning to list in Hong Kong span various industries, including electronics, machinery, pharmaceuticals, food and beverage, chemicals, and media, with the electronics sector being the most concentrated [5][6] - Companies like Kexing Pharmaceutical, a global biopharmaceutical firm, aim to deepen their "innovation + internationalization" strategy through the Hong Kong listing, which will accelerate overseas business development and enhance their international brand image [5][6] Group 3 - Electronic industry firms such as Jinghe Integration and Huqin Technology view the Hong Kong listing as a means to expand overseas customer bases and optimize investment layouts, which is crucial given the fast-paced product iteration and high technology investment in the sector [6] - Leading companies in their respective fields, such as Luxshare Precision and Victory Technology, have submitted H-share applications, with Luxshare Precision's market value exceeding 300 billion yuan and plans to use raised funds for capacity expansion and technological research [6] Group 4 - The new regulations effective from August 4 at the Hong Kong Stock Exchange have improved IPO market pricing and public market rules, enhancing financing flexibility for issuers and strengthening investor protection, which is expected to further encourage A-share companies to list in Hong Kong [6]

Group 1 - Company Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with relevant intermediaries, but specific details are yet to be determined [1] - In the first half of 2025, Kexing Pharmaceutical reported revenue of 700 million yuan, a year-on-year decrease of nearly 8%, while net profit attributable to shareholders increased by 576% to 80.34 million yuan [1] Group 2 - Company Junshi Biosciences has completed the administration of the first patient in the U.S. for the international multi-center Phase II clinical study of HLX43, a PD-L1 antibody-drug conjugate for advanced non-small cell lung cancer [2] - The clinical study is also being conducted in China, with plans to expand to Australia and Japan when conditions permit [2] Group 3 - Company Sanofi Biologics announced that shareholders plan to reduce their holdings by a total of up to 3.43%, with specific reductions from various executives and shareholders scheduled between September 15 and December 14, 2025 [3] - This potential reduction may cause short-term fluctuations in the stock price, while the long-term value will depend on the company's core business developments [3] Group 4 - Company Changshan Pharmaceutical reported a net loss of approximately 29.09 million yuan for the first half of 2025, with revenue of about 492 million yuan, a year-on-year decrease of 13.42% [4] - The company needs to focus on business restructuring and improving product competitiveness to enhance performance and profitability [4] Group 5 - Company Tianyao Pharmaceutical reported a revenue of approximately 1.588 billion yuan for the first half of 2025, a year-on-year decrease of 11.81%, with a net profit of about 49.3 million yuan, down 65.28% [5] - The decline in revenue and net profit is attributed to price reductions from centralized procurement and market competition affecting raw materials, alongside a fine exceeding 69 million yuan due to monopoly issues [5]